I find that the stock price of most small biotech companies will tank upon FDA approval either because shorts are saying that product sales will fall below expectations or because a large secondary will be needed to cover marketing and hiring costs. BUT these should not be issues at all for Leronlimab - upon EUA we will definitely sell our entire product inventory and the quick influx of cash will make a large secondary unnecessary!